Pi Zulan, Johnson James A, Meng Wei, Phillips Monique, Schumacher William A, Bostwick Jeffrey S, Gargalovic Peter S, Onorato Joelle M, Generaux Claudia N, Wang Tao, He Yan, Gordon David A, Wexler Ruth R, Finlay Heather J
Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
ACS Med Chem Lett. 2021 Oct 22;12(11):1766-1772. doi: 10.1021/acsmedchemlett.1c00385. eCollection 2021 Nov 11.
The apelin receptor (APJ) is a significant regulator of cardiovascular function and is involved in heart failure and other cardiovascular diseases. (Pyr)apelin-13 is one of the endogenous agonists of the APJ receptor. Administration of (Pyr)apelin-13 increases cardiac output in preclinical models and humans. Recently we disclosed clinical lead BMS-986224 (), a C3 oxadiazole pyridinone APJ receptor agonist with robust pharmacodynamic effects similar to (Pyr)apelin-13 in an acute rat pressure-volume loop model. Herein we describe the structure-activity relationship of the carboxamides as oxadiazole bioisosteres at C3 of the pyridinone core and C5 of the respective pyrimidinone core. This study led to the identification of structurally differentiated 6-hydroxypyrimidin-4(1)-one-3-carboxamide with pharmacodynamic effects comparable to those of compound .
阿片肽受体(APJ)是心血管功能的重要调节因子,参与心力衰竭和其他心血管疾病。(吡啶基)阿片肽-13是APJ受体的内源性激动剂之一。在临床前模型和人类中,给予(吡啶基)阿片肽-13可增加心输出量。最近我们公布了临床先导化合物BMS-986224(),一种C3恶二唑吡啶酮APJ受体激动剂,在急性大鼠压力-容积环模型中具有与(吡啶基)阿片肽-13相似的强大药效学作用。在此,我们描述了作为吡啶酮核心C3和相应嘧啶酮核心C5处恶二唑生物电子等排体的羧酰胺的构效关系。这项研究导致鉴定出结构上有差异的6-羟基嘧啶-4(1)-酮-3-羧酰胺,其药效学作用与化合物相当。